Evidence Based Beta-Blocker Therapy of Pediatric Heart Failure

Buchhorn R

Department of Pediatric, Caritas Krankenhaus Bad Mergentheim, Germany

*Corresponding Author: Buchhorn R, Department of Pediatric, Caritas Krankenhaus Bad Mergentheim, Germany, E-mail: Reiner.Buchhorn@ckbm.de

1. THE BURDEN OF PEDIATRIC HEART FAILURE

A simplified picture from different sources 1 about the global burden of pediatric heart failure will help us to identify the specific problems in childhood heart failure:

- Two thirds of children who die from heart failure are infants
- The main cause of childhood heart failure in Europe and the US are congenital heart defects (80% overall, 40% left-to-right shunts and 20% complex heart defects)
- The main causes of childhood heart failure in the developing world are acquired heart disease such as anemia and infections
- Heart failure is one of the main causes of infant mortality worldwide

In 2006 we published data from 345 grownups with congenital heart defects that showed a growing incidence of heart failure during follow up 2. Recently long term (60 years!) data for more than 10000 Scandinavian children with operated congenital heart defects showed that 43% of these patients died from heart failure and 20% from sudden cardiac death. Added to this there were 21% fatal perioperative complications. Other problems, such as endocarditis, stroke, aortic dissection, bleeding and embolism playing a subordinate role. The mean age at death of 14 ± 16 years indicates that many patients whose cause of death was heart failure are children. Heart failure indicated by elevated brain natriuretic peptide levels is a marker of prognosis in children 4 and adults with congenital heart disease 5. Cardiovascular mortality is also increased in patients with simple congenital heart defects like ventricular and atrial septal defects 6.

2. CLINICAL TRIALS IN PEDIATRIC HEART FAILURE

Unfortunately, despite the fact that most of the children who died from heart failure in Europe and the US are infants with congenital heart defects, the main focus of heart failure research in pediatric cardiology has been in older children with ventricular dysfunction.23 It is Robert Shaddy who published the first cases of metoprolol treatment for children with cardiomyopathies 7. He initiated the US carvedilol trial 8, a multicenter prospective randomized trial with carvedilol in children older than 1 year and suffering from heart failure from multiple etiologies. Unfortunately he made the same mistake like as I did in the so called BB-GUCH trial 9: Since the partners did not seem to trust beta blocker treatment in childhood heart failure and because they were concerned about the possibility of severe complications both trials recruited children with mild heart failure and low neurohormonal activities indicated by low BNP values. We decide for a cut off value of 100 pg/ml while the mean BNP value of 110 pg/ml in the US carvedilol trial was even lower. As we know today, we need thousands of such NYHA 2 patients and very long-term observation times to find a significant survival benefit in such trials and this will probably never be possible in pediatric cardiology. Nobody can explain why such an underpowered trial with very low dose carvedilol in 106 children with ventricular dysfunction with low BNP values should prove the results from more than 20000 adults with left ventricular dysfunction in well conducted prospective randomized trials 10. However, if we summarize all these underpowered trials with carvedilol in 228 children with left ventricular dysfunctions in a meta-analysis we find the expected survival benefit (OR 0.57; 0.33-0.97) 11. Indeed children are not miniature...
adults, but they are humans: Perhaps for the first time in medical history pediatricians are calling for a life-saving therapy for children to be used only before appropriate child studies are carried out. It shows a degree of cynicism if such studies have not been carried out for more than 20 years.

I could only find 4 prospective randomized trials in infants with heart failure due to congenital heart defects 12-15 (table 1), three of these studies are investigator initiated trials from Germany, Turkey and India. In contrast to enalapril and digoxin, beta blockers improve clinical signs of heart failure and neurohormonal activation. The effect on mortality remains unclear in these small trials, but is similar to the 13% in the enalapril and placebo group of the US trial. For this trial 230 from the 533 infants of the Single Ventricle Reconstruction Trial who were eligible were recruited, and 31 died. The overall one year mortality of 555 infants with a single right ventricle was higher (30%) 16.

Table1. Prospective randomized trials in infants with heart failure due to congenital heart defects.

<table>
<thead>
<tr>
<th></th>
<th>CHF- Pro-Infant 14</th>
<th>US-Enalapril 12</th>
<th>VSD-PHF 15</th>
<th>Elkiran et al 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>20</td>
<td>185</td>
<td>80</td>
<td>37</td>
</tr>
<tr>
<td>Drug</td>
<td>Propranolol/Dig/Diuretics</td>
<td>Enalapril/Placebo</td>
<td>Propranolol/Dig/Diuretics</td>
<td>Digeoxin/Placebo</td>
</tr>
<tr>
<td>Age [Year]</td>
<td>0.2</td>
<td>0.1</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>CHD [%]</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>LRS/SV</td>
<td>SV</td>
<td>VSD</td>
<td>LRS/SV</td>
</tr>
<tr>
<td>BNP [pg/ml]</td>
<td>NT-BNP 17000</td>
<td>BNP 82</td>
<td>?</td>
<td>NT-BNP 1396 2</td>
</tr>
<tr>
<td>Mortality [%]</td>
<td>20</td>
<td>13</td>
<td>3.7</td>
<td>?</td>
</tr>
</tbody>
</table>

3. THE CURRENT TREATMENT OF PEDIATRIC HEART FAILURE

It is unclear what the current practice in childhood heart failure is. I introduced beta blockers in the German guidelines in 2006 and probably Robert Ross introduced them in the Canadian guidelines in 2013. It is certain that preoperative beta blocker treatment remains highly controversial but I am surprised to see that more and more pediatric cardiologists routinely use beta blockers despite criticism from opinion leaders. However, published data from the US show that infants with a single ventricle are treated with diuretics (90%), ACE inhibitors (38%) and Digoxin (28%). Only 4.2% of these infants received propranolol. For left ventricular dysfunction “National Prescribing Trends for Heart Failure Medications in Children” 18 showed an increase in the use of beta blockers from 10% in 2001 to 40% in 2005, but no further increase up to 2010 after publication of the US carvedilol trial. From 13892 pediatric heart failure hospitalisations in the US 1014 children died (7.3%) 19. Pediatric mortality is nearly twice as high as mortality in adults with heart failure 20 due to a 40% mortality reduction by beta blocker treatment measured in high volume clinical trials. The potential of saving 400 children’s lives saved in the US alone should be an order to the opinion leaders in pediatric cardiology rethink their “nihilism” against beta blockers in pediatric heart failure, as recently published 21.

4. EVIDENCE BASED THERAPY OF INFANTS HEART FAILURE BASED UPON HRV ONLINE MONITORING

We use heart rate variability (HRV) online-monitoring on our pediatric intensive care unit (PICU) to predict the impact of beta blockers on heart failure in each individual patient. We recently published our first results and could show that those patients with increasing total power and high frequency power have favorable long-term courses. Such an infant with Down’s syndrome and VSD with a very high NT-Pro BNP value of 101000 pg/ml who was treated with dobutamine due to left ventricular dysfunction is shown in figure 1. We start low dose carvedilol and could stop dobutamine after 24 hours while heart rate variability increase to normal values within one week and NT-Pro BNP decrease rapidly. The baby could be quickly weaned from ventilator and complete breastfeeding was established at the time of admission after 2 weeks. Up to the successful operation, treated with 0.7 mg/kg carvedilol, he was free of clinical heart failure with normal weight gain. The baby was successfully operated at the age of six month.
Today we have such HRV data from 28 infants with severe heart failure who were treated in our PICU after initiation of beta blocker (15 Propranolol, 3 Metoprolol and 1 Carvedilol). Propranolol and Carvedilol were successful in all preoperative infants and HRV increase to normal values as published in 200222. All these infants survive. However HRV remained very low in older infants with a complicated course after heart surgery most of all after palliation of a single ventricle, two of them and the baby with the mitochondriopathy died. Three infants are on metoprolol treated from the university hospitals that performed heart surgery. One infant after biventricular repair of pulmonary atresia had ongoing heart failure despite metoprolol, sildenafil, frusemide, hydrochlorothiazide and oxygen therapy. After 4 month of this unsatisfactory therapy we decide to change the cardio selective beta blocker metoprolol (24mg) to 15mg propranolol. HRV online monitoring on our PICU showed an impressive decrease of heart rate and increase of HRV (figure 3). The clinical improvement gives us the opportunity to stop therapy with sildenafil, frusemide and oxygen. NT-Pro-BNP drop down from 2413 to 837 pg/ml. This case demonstrate that propranolol has extraordinary effects on heart rate and HRV in infants with heart failure compared to cardio selective beta blockers probably of cause its additional effects on B2 - and central B - receptors. Unfortunately other groups didn't proof our extraordinary good results with propranolol in infants with heart failure due congenital heart disease published in a prospective study in 2001 23.
5. AUTONOMIC IMPRINTING--UNTREATED EARLY STRESS HAS LIFELONG CONSEQUENCES

We developed a model called “autonomic imprinting”, recently published in PLOS one 24 that should explain how early life stress impair growth and cognition and enhance the cardiovascular risk in later life.25 Heart failure was only one of different causes of early life stress like intrauterine growth retardation and prematurity. We began to understand the impact of nutrition on the autonomic nervous system 26. Today we are able to show that our concept to prevent and to treat early life stress in children with congenital heart defects has longtime beneficial effects on the autonomic nervous system measured by 24 hour heart rate variability 27;28. We published our complete group (from a little Pediatric Department in Bad Mergentheim) of patients with operated congenital heart disease and cardiomyopathies as shown in figure 4: We changed our concept to treat heart failure in 2004. We intend to improve autonomic imprinting by heart failure with the use of propranolol without any use of diuretics in infants with heart failure. This current concept group with an age up to 12 years is the first complete published group with operated congenital heart disease who had supernormal HRV and obviously no autonomic dysfunction. Nearly 50% of our conventional treated patients with an age between 13 and 40 years have low HRV and in part severe autonomic dysfunction as published by other groups. Children with ventricular dysfunction had the lowest HRV despite beta blocker treatment and died during follow up or need heart transplantation (N=2).

![Figure4](image)

**Figure 4.** 24-hour heart rate variability indicated by the parameter SDNN from our complete group of patients with operated congenital heart defects and/or cardiomyopathies. We changes preoperative therapy of heart failure in 2004 and observe nearly no patients with postoperative autonomic dysfunction during longtime follow up. As published by others groups, many patients with a conventional heart failure treatment in infancy developed autonomic dysfunction during follow up.

**REFERENCES**


